204 related articles for article (PubMed ID: 30910871)
1. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm.
Filì M; Trocme E; Bergman L; See TRO; André H; Bartuma K; Girnita L; All-Eriksson C; Seregard S; Stålhammar G
Br J Ophthalmol; 2020 Jan; 104(1):26-32. PubMed ID: 30910871
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
3. Effect of plaque brachytherapy dose and dose rate on risk for disease-related mortality in 1238 patients with choroidal melanoma.
Filì M; Trocme E; Herrspiegel C; Seregard S; Stålhammar G
Br J Ophthalmol; 2021 Jan; 105(1):57-62. PubMed ID: 32430342
[TBL] [Abstract][Full Text] [Related]
4. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19.
Jampol LM; Moy CS; Murray TG; Reynolds SM; Albert DM; Schachat AP; Diddie KR; Engstrom RE; Finger PT; Hovland KR; Joffe L; Olsen KR; Wells CG;
Ophthalmology; 2020 Apr; 127(4S):S148-S157. PubMed ID: 32200815
[TBL] [Abstract][Full Text] [Related]
5. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.
Nag S; Quivey JM; Earle JD; Followill D; Fontanesi J; Finger PT;
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):544-55. PubMed ID: 12738332
[TBL] [Abstract][Full Text] [Related]
6. Endoresection versus iodine-125 plaque brachytherapy for the treatment of choroidal melanoma.
Caminal JM; Mejia K; Masuet-Aumatell C; Arias L; Piulats JM; Gutierrez C; Pera J; Catala J; Rubio M; Arruga J
Am J Ophthalmol; 2013 Aug; 156(2):334-342.e1. PubMed ID: 23677135
[TBL] [Abstract][Full Text] [Related]
7. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.
Saconn PA; Gee CJ; Greven CM; McCoy TP; Ekstrand KE; Greven KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):844-8. PubMed ID: 20171804
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium-106 plaque radiotherapy alone or in combination with transpupillary thermotherapy in the management of choroidal melanoma.
Gündüz K; Kurt RA; Akmeşe HE; Köse K; Uçakhan-Gündüz O
Jpn J Ophthalmol; 2010 Jul; 54(4):338-43. PubMed ID: 20700803
[TBL] [Abstract][Full Text] [Related]
9. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.
Jampol LM; Moy CS; Murray TG; Reynolds SM; Albert DM; Schachat AP; Diddie KR; Engstrom RE; Finger PT; Hovland KR; Joffe L; Olsen KR; Wells CG;
Ophthalmology; 2002 Dec; 109(12):2197-206. PubMed ID: 12466159
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of choroidal melanomas treated with eye physics: a 20-year review.
Berry JL; Dandapani SV; Stevanovic M; Lee TC; Astrahan M; Murphree AL; Kim JW
JAMA Ophthalmol; 2013 Nov; 131(11):1435-42. PubMed ID: 24008431
[TBL] [Abstract][Full Text] [Related]
11. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
12. Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review.
Vonk DT; Kim Y; Javid C; Gordon JD; Stea B
Brachytherapy; 2015; 14(5):726-33. PubMed ID: 26051804
[TBL] [Abstract][Full Text] [Related]
13. Clinical Predictors of Regression of Choroidal Melanomas after Brachytherapy: A Growth Curve Model.
Rashid M; Heikkonen J; Singh AD; Kivelä TT
Ophthalmology; 2018 May; 125(5):747-754. PubMed ID: 29499831
[TBL] [Abstract][Full Text] [Related]
14. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
15. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma.
Marconi DG; de Castro DG; Rebouças LM; Bernardes Gil GO; Fogaroli RC; Conte Maia MA; Gobo Silva ML; Assis Pellizzon AC; Motono Chojniak MM
Brachytherapy; 2013; 12(3):235-9. PubMed ID: 22436517
[TBL] [Abstract][Full Text] [Related]
16. Small choroidal melanoma: outcomes following apical height dose brachytherapy.
Yupari RJ; Bena J; Wilkinson A; Suh J; Singh A
Br J Ophthalmol; 2021 Aug; 105(8):1161-1165. PubMed ID: 32878827
[TBL] [Abstract][Full Text] [Related]
17. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients.
Kwon HJ; Ko JS; Kim M; Lee CS; Lee SC
Br J Ophthalmol; 2013 May; 97(5):653-8. PubMed ID: 23428983
[TBL] [Abstract][Full Text] [Related]
19. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
[No Abstract] [Full Text] [Related]
20. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
